Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 31,400 shares, an increase of 175.4% from the March 31st total of 11,400 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 191,800 shares, the short-interest ratio is presently 0.2 days.
Novozymes A/S Stock Performance
NVZMY traded up $1.13 during trading on Friday, hitting $66.04. The stock had a trading volume of 15,150 shares, compared to its average volume of 30,298. The stock has a 50 day simple moving average of $60.14 and a two-hundred day simple moving average of $59.06. Novozymes A/S has a twelve month low of $53.95 and a twelve month high of $72.50. The company has a market capitalization of $30.93 billion, a PE ratio of 41.80, a PEG ratio of 3.87 and a beta of 0.91.
Novozymes A/S Increases Dividend
The firm also recently announced a dividend, which was paid on Wednesday, April 23rd. Investors of record on Monday, April 7th were paid a dividend of $0.3758 per share. This is an increase from Novozymes A/S's previous dividend of $0.17. The ex-dividend date of this dividend was Monday, April 7th. Novozymes A/S's payout ratio is 47.47%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
See Also
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.